Royal Bank of Canada Sells 78,803 Shares of Omnicell, Inc. $OMCL

Royal Bank of Canada lessened its position in Omnicell, Inc. (NASDAQ:OMCL) by 12.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 532,172 shares of the company’s stock after selling 78,803 shares during the quarter. Royal Bank of Canada’s holdings in Omnicell were worth $17,763,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its stake in Omnicell by 6.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the period. Wellington Management Group LLP raised its holdings in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares in the last quarter. Lazard Asset Management LLC lifted its position in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after buying an additional 27,497 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Omnicell by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock valued at $51,088,000 after buying an additional 11,424 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

OMCL has been the topic of a number of recent research reports. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Craig Hallum reissued a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Wells Fargo & Company decreased their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Omnicell in a report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.

Insider Activity

In other news, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the sale, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by insiders.

Omnicell Trading Down 2.7%

NASDAQ OMCL opened at $36.16 on Friday. Omnicell, Inc. has a 12 month low of $29.06 and a 12 month high of $55.00. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The stock’s fifty day moving average price is $41.41 and its 200-day moving average price is $40.63. The stock has a market cap of $1.64 billion, a P/E ratio of 43.05, a P/E/G ratio of 1.01 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.Omnicell’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities analysts forecast that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.